The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
 
Anna Maloney
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Miklos C. Fogarasi
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Bristol-Myers Squibb; Evaxion Biotech; Immunetune; LG Chem; Merck; Novartis
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Oncorus; Pfizer (Inst); Xencor
Expert Testimony - Boehringer Ingelheim
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - AstraZeneca; Bioentre; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Corner Therapeutics; Curis; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Kairos Therapeutics; Merck Sharp & Dohme; Novartis; Rheos Medicines; Surface Oncology; Zumutor Biologics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Tamara A. Sussman
No Relationships to Disclose
 
Ann W. Silk
Consulting or Advisory Role - Instil Bio; Signatera
Research Funding - Biohaven Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Morphogenesis (Inst); Replimune (Inst); Shattuck Labs (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Rizwan Haq
No Relationships to Disclose
 
David Liu
No Relationships to Disclose
 
Megan Leigh Insco
No Relationships to Disclose
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Takeda (I)
Consulting or Advisory Role - Instil Bio; Iovance Biotherapeutics; Merck; Nektar; Novartis; Sanofi; Xilio Therapeutics
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis